Urothelial Cancer

The Gabrail Cancer Center currently has many Clinical Trial opportunities . For more information and to see if you qualify call Carrie Smith R.N., Director of Research at 330-492-3345 x 208 or  via email
CSmith@GabrailCancerCenter.com.

A STUDY OF ENFORTUMAB VEDOTIN (ASG-22CE) AS MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER THERAPIES FOR THE TREATMENT OF UROTHELIAL CANCER

A PHASE 1B, MULTICENTER, TWO-PART, OPEN-LABEL STUDY OF DS-8201A, AN ANTI-HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR-2 (HER2)-ANTIBODY DRUG CONJUGATE (ADC), IN COMBINATION WITH NIVOLUMAB, AN ANTI-PD-1 ANTIBODY, FOR SUBJECTS WITH HER2-EXPRESSING ADVANCED BREAST AND UROTHELIAL CANCER

Return to Clinical Trials at GCC